The latest biotech news - Labiotech.eu

Home News and Trends Page 198

Latest Posts

victoria shennan anthropocene microbial music

News and Trends 1 Sep 2018

A Symphony Inspired by the Microbes Living on Us

British artist Victoria Shennan has created a musical composition based on the microorganisms that form an essential part of us. We are just starting to realize the huge role that microorganisms play in our well-being and the proper functioning of our bodies. Research on the human microbiome in the last decade has linked the […]

September 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Genomics partner Vertex big genomic data

News and Trends 31 Aug 2018

Vertex Partners Oxford Genome Analysis Firm To Develop New Personalized Therapies

Genomics, a company using machine learning to analyze genetic data, is partnering with precision medicine specialists Vertex Pharmaceuticals to develop new therapies in a 3-year collaboration. The agreement marks the closing of the Oxford-based company’s €28M (£25M) series B fundraising round, as Vertex has also invested €11.7M (£10.5M) in Genomics. If the collaboration is successful […]

August 31, 2018 - 2 minutesmins - By Helen Albert

Alnylam 300 Third Street Cambridge 1

News and Trends 30 Aug 2018

First RNAi Drug Approved in Europe After 20 Years of Research

The first ever RNA interference (RNAi) drug, used to treat polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis, has been given marketing approval by the European Commision. The approval follows that of the US FDA who gave the green light to US biotech Alnylam Pharmaceutical’s Onpattro (patisiran) earlier this month following positive Phase III findings in […]

August 30, 2018 - 3 minutesmins - By Helen Albert

Menopause header KaNDy

News and Trends 29 Aug 2018

Women’s Health Biotech Raises €28M to Fund Phase II Menopause Drug Trial

UK-biotech KaNDy Therapeutics closed a £25M (€28M) series C round to help finance the upcoming Phase IIb trial of its lead candidate for treating symptoms of the menopause. Unlike other therapies aimed at treating the same symptoms, KaNDy’s drug (NT-814) is not based on hormone replacement therapy, which can take a long time to be […]

August 29, 2018 - 2 minutesmins - By Helen Albert

Lymphocytes and cancer cells Affimed

News and Trends 29 Aug 2018

Affimed Collaborates with Genentech in Cancer Immunotherapy Deal Worth €4.4B

The German biotech will partner with Genentech, part of the Roche Group, to develop targeted cancer therapies that engage both innate and adaptive immune cells. Affimed will receive €82M ($96M) upfront from the US giant to develop its immunotherapy ROCK (Redirected Optimized Cell Killing) platform, which uses both natural killer cells and T-cells to target […]

August 29, 2018 - 2 minutesmins - By Helen Albert

CAR T Cell Therapy Europe

News and Trends 28 Aug 2018

Update: Gilead and Novartis’s CAR T-Cell Therapies Approved in Europe

Update: Following on from earlier approvals in the US, the European Commission announced it has given marketing approval for both Gilead’s Yescarta and Novartis’s Kymriah for treatment of patients with various forms of blood cancer. Yescarta (axicabtagene ciloleucel) can be used to treat adults with a relapsed or refractory form of the blood cancer diffuse large […]

August 28, 2018 - 4 minutesmins - By Editorial Team

ADVERTISEMENT

Fungal Futures Sustainable Materials

News and Trends 25 Aug 2018

Are Fungi the Answer to a More Sustainable Future?

The exhibition Fungal Futures, in Belgium, showcases multiple objects that are made using fungi, offering a peek into a future of sustainable materials. We are in dire need of sustainable materials that provide an environmentally-friendly alternative to plastic and other materials that cause pollution and end up crowding landfills. The solution could be fungi. These […]

August 25, 2018 - 5 minutesmins - By Clara Rodríguez Fernández

Rheumatoid arthritis Immunovia

News and Trends 22 Aug 2018

Swedish Biotech Breaks Barrier to Diagnosis with Rheumatoid Arthritis Test

A blood test developed by Swedish-biotech Immunovia and scientists from Linköping University accurately diagnoses patients with rheumatoid arthritis even if they test negative for two common biomarkers. The current gold standard test for rheumatoid arthritis, which affects 5-7 million people in the US and Europe, misses a substantial number of people who have the condition. […]

August 22, 2018 - 2 minutesmins - By Helen Albert

type 2 diabetes betagenon2 1

News and Trends 17 Aug 2018

Novo Nordisk Buys British ‘Smart’ Insulin Diabetes Biotech in deal worth €702M

Novo Nordisk acquired the UK biotech Ziylo, which develops glucose-responsive insulin treatments for diabetes that act in response to changes in blood sugar levels. The Danish big-pharma, which is already a big player in the diabetes space, acquired the full rights to Ziylo’s technology in a deal worth up to €702M ($800M). Novo will use the […]

August 17, 2018 - 2 minutesmins - By Alexander Burik

mRNA Flu Vaccine Cover

News and Trends 16 Aug 2018

Pfizer Offers €374M for German mRNA Flu Vaccine

BioNTech, based in Mainz, Germany, has entered into a partnership with Pfizer worth up to $425M (€374M) to develop an mRNA-based flu vaccine, which could be produced much more quickly than current flu vaccines. Messenger RNA (mRNA) is one of the building blocks living organisms use to create proteins from genes. BioNTech is developing prophylactic […]

August 16, 2018 - 2 minutesmins - By Alexander Burik

hiv cartoon Sur fi

News and Trends 15 Aug 2018

London Biotech Gets Positive Phase III Results for its Monthly HIV Treatment

ViiV Healthcare has shown its monthly two-drug HIV treatment works as well as a daily three-drug treatment, which could help reduce the total number of drugs taken by patients. In a Phase III trial that recruited 618 people, London biotech ViiV Healthcare aimed to see if adult HIV-positive patients who had been taking daily antiretroviral […]

August 15, 2018 - 2 minutesmins - By Alexander Burik

Orchard cover image

News and Trends 13 Aug 2018

Orchard Therapeutics Raises €132M to Develop Gene Therapies

Orchard Therapeutics raised $150M (€132M) in Series C financing to bring its gene therapies from clinical testing to regulatory approval. The British biotech will use the funding to develop its most advanced clinical programs, which aim to treat rare inherited metabolic and immune system diseases. The news follows Orchard’s acquisition of GSK’s entire gene therapy […]

August 13, 2018 - 2 minutesmins - By Alexander Burik

ADVERTISEMENT